GlaxoSmithKline's top scientists have staked out a pioneering role in an incipient field in the drug discovery world, rolling out a slate of new initiatives designed to sound the starting gun in a long-running effort to develop new therapeutics that can fight disease by targeting the electrical signals that harmonize human biology.
EvaluatePharma researchers totted up sales for the last 5 years' worth of analysts' blockbuster picks--and found plenty of bad bets.
After keeping its mid-stage data for a closely-watched and controversial drug for Duchenne muscular dystrophy under wraps, GlaxoSmithKline has pulled back part of the covers to reveal that drisapersen did in fact hit the primary endpoint on walking distance.
The two groups have been working together for the past decade, helping build the city-state's reputation for R&D.
A pilot study has brought dispiriting news for proponents of boosting vaccine adherence through text messaging. A study found that a series of text message prompts failed to increase vaccination rates among pregnant women.
How can GlaxoSmithKline jump-start Benlysta? Apparently by developing the lupus drug as a treatment for an entirely different disease. The drugmaker said it has launched a Phase III study of the drug in patients with a type of vasculitis.
Drugmakers are circling Optimer Pharmaceuticals, the antibiotics maker that says it's considering a sale. And that includes GlaxoSmithKline, Astellas Pharma, AstraZeneca and Cubist Pharmaceuticals, Bloomberg sources say, for a deal worth as much as $1 billion.
The Swedish regulator has added to evidence linking GlaxoSmithKline's swine flu vaccine to narcolepsy in a registry study of 5.8 million people.
Russia is a coveted, if challenging, market for drugmakers looking for new sources of revenue. Its double-digit market growth has not escaped the notice of Japan's Eisai, which is planning a major launch of a number of its products there.
As part of an ambitious effort to prep for a future pandemic, GlaxoSmithKline and Texas A&M are teaming up to build a $91 million flu vaccine manufacturing center in the Lone Star state that will rely on cell-culture lines rather than chicken eggs.